CRMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cormedix's Asset Impairment Charge for the three months ended in Mar. 2024 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
The historical data trend for Cormedix's Asset Impairment Charge can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cormedix Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Asset Impairment Charge | Get a 7-Day Free Trial | - | - | - | - | - |
Cormedix Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Asset Impairment Charge | Get a 7-Day Free Trial | - | - | - | - | - |
Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.
Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Thank you for viewing the detailed overview of Cormedix's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.
Alan W Dunton | director | VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406 |
Erin Mistry | officer: Chief Commercial Officer | 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922 |
Joseph Todisco | director, officer: Chief Executive Officer | 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Myron Kaplan | director | C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176 |
Paulo F Costa | director | MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Robert A Stewart | director | 360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960 |
Janet Dillione | director | ONE WAYSIDE ROAD, BURLINGTON MA 01803 |
Matthew T David | officer: EVP, Chief Financial Officer | 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922 |
Elizabeth Masson | officer: EVP, Head of Clinical Ops. | 400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922 |
Thomas Nusbickel | officer: EVP, Chief Commercial Officer | 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922 |
Gregory Scott Duncan | director | 44 MILTON AVENUE, ALPHARETTA GA 30009 |
Steven W Lefkowitz | director | SIX HARRISON STREET, NEW YORK NY 10013 |
Mehmood Khan | director | 700 ANDERSON HILL ROAD, PURCHASE NY 10577 |
Armstrong Jr. John L. | officer: Exec VP of Tech Operations | C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921 |
Khoso Baluch | director, officer: Chief Executive Officer | 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921 |
From GuruFocus
By sperokesalga sperokesalga • 05-08-2023
By Marketwired • 08-08-2023
By Stock market mentor Stock market mentor • 01-17-2023
By Marketwired • 09-06-2023
By sperokesalga sperokesalga • 04-26-2023
By sperokesalga sperokesalga • 04-17-2023
By sperokesalga sperokesalga • 06-21-2023
By Value_Insider Value_Insider • 12-06-2022
By Marketwired • 06-28-2023
By sperokesalga sperokesalga • 05-30-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.